Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
ConclusionsAmong elderly Medicare patients with advanced RCC, first-line pazopanib tretament was associated with significantly longer OS, as well as lower healthcare costs and HRU, compared with first-line sunitinib treatment.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Drugs & Pharmacology | Healthcare Costs | Kidney Cancer | Medicare | Renal Cell Carcinoma | Toxicology